Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Net Income: 2021-2025

Historic Net Income for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to -$12.1 million.

  • SAB Biotherapeutics' Net Income fell 16.60% to -$12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.6 million, marking a year-over-year increase of 6.57%. This contributed to the annual value of -$41.9 million for FY2024, which is 0.59% up from last year.
  • SAB Biotherapeutics' Net Income amounted to -$12.1 million in Q3 2025, which was down 23.35% from -$9.8 million recorded in Q2 2025.
  • SAB Biotherapeutics' Net Income's 5-year high stood at $1.4 million during Q1 2021, with a 5-year trough of -$22.9 million in Q4 2023.
  • Over the past 3 years, SAB Biotherapeutics' median Net Income value was -$9.8 million (recorded in 2025), while the average stood at -$9.8 million.
  • As far as peak fluctuations go, SAB Biotherapeutics' Net Income tumbled by 845.93% in 2023, and later spiked by 56.50% in 2024.
  • Quarterly analysis of 5 years shows SAB Biotherapeutics' Net Income stood at -$11.6 million in 2021, then surged by 32.05% to -$7.8 million in 2022, then tumbled by 191.21% to -$22.9 million in 2023, then surged by 56.50% to -$9.9 million in 2024, then decreased by 16.60% to -$12.1 million in 2025.
  • Its Net Income was -$12.1 million in Q3 2025, compared to -$9.8 million in Q2 2025 and -$10.8 million in Q1 2025.